UNSPSC 51333103: Panamesine

This classification denotes an antipsychotic agent with the molecular formula C23H26N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 023D9E916L chemically known as (5s)-5-((4-hydroxy-4-(3,4-(methylenedioxy)phenyl)piperidino)methyl)-3-(p-methoxyphenyl)-2-oxazolidinone but generally known as panamesine, which bears US NIH Compound Identifier 3047810. European Medicines Agency schedules Panamesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09601MIG.

UNSPSC 51333103 Panamesine is a Commodity code that describes pharmaceutical products, but recent state and local opportunities show no activity actually purchasing panamesine itself. Instead, the code appears to be a catch-all classification for varied pharmaceutical procurement that state and local governments are conducting: naloxone and drug deactivation systems for emergency response, direct-to-manufacturer prescription fulfillment programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing frameworks.

Activity spans health departments, state agencies, and cooperative purchasing alliances across Florida, Texas, and the Upper Midwest. Seminole County, Florida issued an IFB on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring electronic bidding and including potential FEMA funding with federal compliance obligations. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026 to explore vendor capabilities for direct-to-manufacturer prescription contracts outside traditional pharmacy benefit manager and group purchasing organization channels—a preliminary market-intelligence exercise before formal RFP release. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP with a March 26, 2026 response deadline to establish statewide and multi-state contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with product availability required by May 15, 2026 and awards effective July 1, 2026. The MMCAP procurement weights price competitiveness at 75 percent and requires vendors to maintain specific insurance thresholds ($5 million general liability, $2 million network security and privacy liability, $2 million professional liability) and comply with cGMP and Drug Supply Chain Security Act certification. The code shows limited recent volume but indicates ongoing state and local interest in pharmaceutical supply chain innovation, emergency-response medications, and cooperative purchasing efficiency across health and human services operations.